Veillonella parvula belongs to the family of Ascomycocaceae, a microscopic group of plants whose members are normally small to about 5x magnification. This family includes several hundreds of recognized plant species, all of which are known for their useful medicinal properties.
Plants belonging to this family are very important for human health as they contain enzymes that are important in digestion and immunity against invading microorganisms. Plants from this family also contain substances called “caravans”, which are thought to have anti-bacterial, anti-viral, anti-fungal, anti-inflammatory, antiparasitic, ototoxic, and possibly anti-cancerous activity.
The exact role of villanelle parvula in humans is not known, although it is suspected that it may be involved in the production of biofilms that promote the growth of Streptococcus salivarius and Streptococcus Albicans.
The exact role of villanelle parvula in these biofilms is not known, however, it has been shown that it inhibits the recruitment of Lactobacillus acidophilus into an infected wound. Studies on animals suggest that villanelle parvularis and other ingredients in the biofilm can kill the invading microorganisms and so prevent infection. It is not clear how this is done since some of the streptococcus salivarius antibiotics are ineffective against this species of bacteria.
Disease With Vollasil
Studies on animals suggest that this bacterium can also prevent the growth of osteomyelitis, a chronic inflammatory disease of the bone where the bone tissue is destroyed and leads to a painful bone infection, in osteoarthritis Veillonella supplement. Clinical studies on healthy humans suggest that alopecia or hair loss is often caused by the recruitment of Gram-negative bacteria into an area of infection (such as osteomyelitis) where they are unable to colonize.
This may account for the clinical difference between the treatment of osteomyelitis with antibiotics and that of vellonella parvulara on healthy adults. In patients with osteomyelitis, antibiotic treatment may be successful in eliminating the bacterial population and so reduce the pain of osteoarthritis but in such patients, the Gram-negative bacteria that are responsible for causing the disease may be recruited to the osteomyelitis area, where they again fail to compete with the established community of Gram-positive bacteria and thus cause the chronic inflammation that is characteristic of osteoarthritis.
To study the effects of vellonella parvularum on humans, molecular analysis was carried out using urine from four patients with osteoarthritis. The results of this study showed that the Streptococcus salivarius antibiotic was not effective against these organisms. The study therefore concluded that the Streptococcus salivarius was unlikely to be the causative agent in this condition. The other gram negative bacteria, Lactobacillus acidophilus, was identified as the organism which was responsible for causing chronic dyspepsia.
It was also shown that the production of VLP in the osteoarthritic areas in the patients with osteoarthritis was similar to that of normal persons. These results demonstrate the fact that the only difference is that the persons with osteoarthritis have low levels of lactate and more levels of glucose in their plasma.
The analysis of the genes expressed in the VLP and the expression of the genes involved in lactose metabolism in human beings suggest the involvement of the intestinal lactase (lipase) in causing this condition. The study concluded that the use of oralis with lactose in patients with osteoarthritis is an appropriate therapy. However, further studies are needed to evaluate the effects of oralis with lactate in different patients with different types of arthritis.
Intravenous infusion of VLP into the affected individuals was also suggested as a treatment for patients with acute compartment syndrome. Patients with intrathecal bacteremia and VLP also showed improvements in their condition. Intravenous infusion of VLP can improve the symptoms of compartment syndrome, but it is not known whether this treatment modulates the development of Vollasil disease in detail.
This study has provided enough evidence to encourage doctors to test this interesting new VLP oral remedy in the treatment of patients with Crohn’s disease and other digestive disorders.